semaglutide tupelo ms Treatment in Tupelo, Tupelo Wellness (@TupeloWellness) • Facebook
Description
A decrease in LAV was observed in the HFrEF population (WMD: -5.4 ml [95% CI: -8.8, -2.0]
This was prompted by the publication of a landmark article in the New England Journal of Medicine addressing the impact of this medication in a large clinical trial
Notable Articles of 2024: FLOW trial In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and death from any cause while slowing loss of kidney function.
Associated with better metabolic outcomes including weight, glucose, BMI, and blood pressure in clinical trials
Weight loss becomes harder with hypothyroidism, but GLP-1 medications like semaglutide can still help when thyroid levels are managed
